A Phase 1 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors

Administered By

Awarded By

Contributors

Start/End

  • October 3, 2017 - September 17, 2020